The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.本發明提供式0化合物及其各種實施例及包含式0化合物及其各種實施例之組合物。在式0化合物中，基團R1A、R1B、R1C、R1D、R2、R3、R4、R5及R6具有如本文中所述之意義。本發明亦提供使用式0化合物及包含式0化合物之組合物作為DLK抑制劑及治療神經退化疾病及病症之方法。
